Cytokinetics (CYTK) stock closes up 3.5% into year-end as Myqorzo launch nears, insider sale disclosed
2 January 2026
2 mins read

Cytokinetics (CYTK) stock closes up 3.5% into year-end as Myqorzo launch nears, insider sale disclosed

NEW YORK, January 1, 2026, 21:17 ET — Market closed

  • Cytokinetics shares last closed up 3.5% at $63.54, ahead of the company’s planned January commercial launch of Myqorzo. 1
  • A regulatory filing showed EVP Andrew Callos sold 1,809 shares under a prearranged trading plan. 2
  • Investors are watching for U.S. pricing details, early prescriptions and the next earnings update expected in late February. 3

Cytokinetics, Incorporated shares ended Wednesday up 3.5% at $63.54, the final U.S. trading session of 2025, after markets closed Thursday for the New Year’s Day holiday. The stock has traded between $29.31 and $70.98 over the past 52 weeks, according to market data. 1

The year-end move matters because Cytokinetics is weeks away from its first full-scale commercial test. Investors have been valuing the biotech on clinical data and regulatory milestones; the next swing factor is execution in the field.

In mid-December, the company said the U.S. Food and Drug Administration approved Myqorzo (aficamten) for adults with symptomatic obstructive hypertrophic cardiomyopathy, a heart muscle disease that can block blood flow. The drug carries a boxed warning for risk of heart failure and is available only through a Risk Evaluation and Mitigation Strategy (REMS), a safety program that can require additional monitoring. “This is a historic moment for our company and for the patients we serve,” Chief Executive Robert I. Blum said at the time. 4

A Form 4 filing dated Dec. 30 showed Executive Vice President and Chief Commercial Officer Andrew Callos sold 1,809 shares at an average price of $62.44 on Dec. 29. The filing showed Callos still held 51,353 shares after the transaction. 2

The form indicated the sale was made under a Rule 10b5-1 plan, a preset instruction that allows insiders to trade on a schedule set in advance, rather than at their discretion.

Myqorzo is entering a market already served by Bristol Myers Squibb’s Camzyos, with Cytokinetics aiming to carve out share as doctors compare labels, monitoring requirements and real-world tolerability. The company has said it plans to announce U.S. pricing details before the launch. 3

That makes the next few weeks a “tell” for demand: how quickly specialist centers write first prescriptions, what insurers require for coverage, and whether REMS administration proves a speed bump or a manageable step in routine care.

Technically, Cytokinetics is trading close to its 50-day moving average of about $63 and well above its 200-day moving average near $46, levels traders often use to gauge short- and long-term momentum. 5

Outside the U.S., Cytokinetics has pointed to pending regulatory milestones that could affect sentiment in 2026. In Europe, the company said the CHMP backed Myqorzo in December and that a European Commission decision is expected in the first quarter. 6

In China, Cytokinetics said an approval earlier in December triggered a $7.5 million milestone payment from Sanofi under their Greater China licensing deal. 7

The next scheduled financial checkpoint is earnings. Cytokinetics has not confirmed a date, but Zacks Investment Research estimates results on Feb. 26, with a forecast loss of $1.48 per share. 8

Before the next session on Friday, traders will also watch the macro tape. The Institute for Supply Management’s December manufacturing index is due at 10 a.m. ET, a read that can move rates and risk appetite across growth stocks. 9

The next major U.S. data point is the December jobs report on Jan. 9 at 8:30 a.m. ET, which can influence interest-rate expectations that often bleed into biotech valuations. 10

For Cytokinetics, the nearer-term catalysts remain company-specific: a pricing update, first-week prescription trends once Myqorzo ships, and any new regulatory or SEC filings that add clarity around launch execution.

Stock Market Today

XRP price today slips near $1.42 as thin weekend liquidity keeps traders on edge

XRP price today slips near $1.42 as thin weekend liquidity keeps traders on edge

7 February 2026
XRP fell about 5% Saturday to $1.42, extending a 22% weekly drop as thin liquidity and macro jitters drove sharp swings. Bitcoin rebounded above $70,000 after a brief plunge, while ether surged 12%. Ripple outlined plans for an “Institutional DeFi” roadmap, including a new lending protocol and permissioned DEX. The Federal Reserve held rates steady last week, with officials signaling caution on inflation.
Home Depot stock price: jobs, inflation and a Feb. 24 earnings test loom

Home Depot stock price: jobs, inflation and a Feb. 24 earnings test loom

7 February 2026
Home Depot shares rose 0.7% to $385.15 Friday, trading between $379.10 and $386.37. Investors await a delayed U.S. jobs report Wednesday and CPI data Friday, both postponed by a brief government shutdown. Home Depot reports fourth-quarter earnings Feb. 24. The Dow closed above 50,000 for the first time.
JPMorgan stock price jumps 4% into weekend as Wall Street braces for a busy data week

JPMorgan stock price jumps 4% into weekend as Wall Street braces for a busy data week

7 February 2026
JPMorgan shares rose 3.95% to $322.40 Friday, outpacing other major banks as U.S. stocks rallied and the Dow closed above 50,000 for the first time. The bank recently completed a $3 billion subordinated notes offering. Investors are watching for delayed U.S. jobs data and inflation figures next week, ahead of JPMorgan’s Feb. 23 company update.
AbbVie stock price: ABBV ends week near $223 after earnings swing — what to watch next

AbbVie stock price: ABBV ends week near $223 after earnings swing — what to watch next

7 February 2026
AbbVie shares rose 2% to $223.43 Friday, capping a volatile week marked by earnings and drug sales scrutiny. Moody’s upgraded AbbVie’s credit rating to A2, citing strong performance in immunology and neuroscience. Investors remain focused on Skyrizi and Rinvoq growth amid rising competition and recent regulatory filings. Trading volume stayed below average, with the stock still 9% off its 52-week high.
Polestar stock (PSNY) jumps on BBVA stake filing as Geely-backed funding stays in focus
Previous Story

Polestar stock (PSNY) jumps on BBVA stake filing as Geely-backed funding stays in focus

PBF Energy stock ends 2025 up 4% as Wall Street reopens Friday — what to watch next
Next Story

PBF Energy stock ends 2025 up 4% as Wall Street reopens Friday — what to watch next

Go toTop